Managing risks in biotechnology: can we learn from nuclear power?

Galina Gaivoronskaia (Institute of Political and Social Sciences, Norwegian University of Science and Technology (NTNU), Dragvoll, N‐7491 Trondheim, Norway)
Knut Erik Solem (Institute of Political and Social Sciences, Norwegian University of Science and Technology (NTNU), Dragvoll, N‐7491 Trondheim, Norway)

Foresight

ISSN: 1463-6689

Publication date: 1 February 2001

Abstract

The potential of biotechnology to cure disease and feed the Third World has not eased public disquiet about its safety. In the rush to commercialization, can lessons be learnt from the introduction of nuclear power a generation ago? While France’s nuclear programme stayed on track, America’s was derailed by accidents and corporate secrecy. So is an industry under state control safer than one in private hands? And in the absence of clear evidence about the long‐term effects of genetic manipulation, how can we design a consultation process that addresses public concerns?

Keywords

Citation

Gaivoronskaia, G. and Erik Solem, K. (2001), "Managing risks in biotechnology: can we learn from nuclear power?", Foresight, Vol. 3 No. 1, pp. 33-45. https://doi.org/10.1108/14636680110802978

Download as .RIS

Publisher

:

MCB UP Ltd

Copyright © 2001, MCB UP Limited

To read the full version of this content please select one of the options below

You may be able to access this content by logging in via Shibboleth, Open Athens or with your Emerald account.
To rent this content from Deepdyve, please click the button.
If you think you should have access to this content, click the button to contact our support team.